Fever Back Pain Children
7
Aug/100
Aug/100

Merck boceprevir both pivotal phase III registration studies in response to chronic hepatitis C primary endpoint Merck announced today that two fundamental Phase III registration boceprevir studies, the experimental oral protease inhibitor for hepatitis C have been completed and met the primary endpoints: two Studies in chronic hepatitis C patients (HCV) genotype 1 infection, the addition of boceprevir treatment with PEG-INTRON and REBETOL ® ® significantly increased the number of patients …
My miracle baby